BCM Gastroenterology & Hepatology Board Review Course 2026

Needs Statement

A course designed for physicians, trainees, and allied health professionals with interest or clinical practice in Gastroenterology and Hepatology. This course will serve as an update on latest diagnostic and therapeutic issues in GI and Hepatology. This program has been developed using a combination of lecture and case based curriculum designed to serve as an intensive review tool for GI and Hepatology Board Certification/Re-Certification Examination in 2026.

Educational Objectives

At the conclusion of the conference, participants should be able to:

• Evaluate and manage esophageal disorders including esophageal motility and functional disorders, GERD and reflux testing, Barrett's esophagus and esophageal neoplasms, and esophageal conditions such as foreign body impaction, eosinophilic esophagitis, and esophageal infections.
• Diagnose and manage gastric conditions including non-variceal upper GI bleeding and peptic ulcer disease, gastric motility and functional disorders, subepithelial lesions (gastric polyps, stromal tumors, and gastric neuroendocrine tumors), and gastric cancer with associated mucosal disorders such as intestinal metaplasia and Helicobacter pylori infection.
• Recognize and manage small bowel and inflammatory conditions including chronic diarrhea, celiac disease, small bowel infections, benign and malignant small bowel neoplasms, vascular disorders of the small bowel, inflammatory bowel disease, and non-IBD colitis.
• Evaluate and manage colorectal conditions including colorectal motility and functional disorders (IBS and SIBO), colon polyps, colorectal cancer, hereditary colorectal cancer and polyposis syndromes, and diverticular disease with lower GI bleeding.
• Diagnose and manage pancreaticobiliary disorders including pancreatic neoplasms and cysts, acute and chronic pancreatitis, and gallbladder and biliary disease.
• Identify and manage parenchymal and metabolic liver diseases including primary sclerosing cholangitis, autoimmune hepatitis, drug-induced liver injury, vascular liver disease, inherited liver diseases (iron overload, Wilson disease, alpha-1 antitrypsin deficiency, cystic fibrosis, and sickle cell hepatopathy), steatotic liver disease (MASLD), viral hepatitis, liver histopathology, and liver masses.
• Evaluate and manage acute and decompensated liver disease including acute liver failure, liver transplantation, liver disease in pregnancy, and complications of portal hypertension such as variceal bleeding, ascites, hepatic encephalopathy, hepatorenal syndrome, and portopulmonary hypertension.
• Apply principles of informed consent, medical ethics, and biostatistics to clinical decision-making and evidence-based practice in gastroenterology and hepatology.

Target Audience

Competencies

• Medical Knowledge
• Patient Care and Procedural Skills
• Practice-Based Learning and Improvement
• Professionalism
• Provide Patient-Centered Care
• Quality Improvement
• Systems-Based Practice
• Utilize Informatics
• Work in Interdisciplinary Teams

Activity Evaluation

Evaluation by questionnaire will address program content, presentation, and possible bias.

Educational Methods

• Lectures
• Case Presentations
• Panel Discussion

Accreditation/Credit Designation

AMA PRA Category 1 Credit™

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Ethics
The presentation, Informed Consent, Ethics, and Biostatistics, has been designated by Baylor College of Medicine for 0.25 credit of education in medical ethics and/or professional responsibility.

ABIM MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.